Neuphoria Therapeutics Inc (NEUP)

Currency in USD
4.1900
+0.0200(+0.48%)
Closed·
4.19000.0000(0.00%)
·
NEUP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.12404.2500
52 wk Range
3.645021.4004
Key Statistics
Prev. Close
4.17
Open
4.17
Day's Range
4.124-4.25
52 wk Range
3.645-21.4004
Volume
37.16K
Average Volume (3m)
1.53M
1-Year Change
-4.5558%
Book Value / Share
5.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NEUP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.7667
Upside
+133.09%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year

Neuphoria Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Neuphoria Therapeutics Inc Company Profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer’s disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.

Compare NEUP to Peers and Sector

Metrics to compare
NEUP
Peers
Sector
Relationship
P/E Ratio
−2.4x−1.8x−0.6x
PEG Ratio
0.000.000.00
Price/Book
1.8x1.6x2.6x
Price / LTM Sales
1.4x179.6x3.4x
Upside (Analyst Target)
67.1%230.6%42.0%
Fair Value Upside
Unlock7.6%5.0%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 9.7667
(+133.09% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Lucid Capital Markets
Hold2.30-45.11%81.00DowngradeOct 21, 2025

Earnings

Latest Release
Nov 14, 2025
EPS / Forecast
-4.41 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NEUP Income Statement

People Also Watch

8.750
BCOMF
0.00%
18.010
SMX
-10.04%
73.26
LRN
+0.45%
8.01
VNDA
-1.11%
21.640
ISSC
+2.22%

FAQ

What Is the Neuphoria Therapeutics (NEUP) Stock Price Today?

The Neuphoria Therapeutics stock price today is 4.1900

What Stock Exchange Does Neuphoria Therapeutics Trade On?

Neuphoria Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Neuphoria Therapeutics?

The stock symbol for Neuphoria Therapeutics is "NEUP."

What Is the Neuphoria Therapeutics Market Cap?

As of today, Neuphoria Therapeutics market cap is 22.53M.

What Is Neuphoria Therapeutics's Earnings Per Share (TTM)?

The Neuphoria Therapeutics EPS (TTM) is -5.09.

From a Technical Analysis Perspective, Is NEUP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Neuphoria Therapeutics Stock Split?

Neuphoria Therapeutics has split 0 times.

How Many Employees Does Neuphoria Therapeutics Have?

Neuphoria Therapeutics has 8 employees.

What is the current trading status of Neuphoria Therapeutics (NEUP)?

As of Jan 24, 2026, Neuphoria Therapeutics (NEUP) is trading at a price of 4.1900, with a previous close of 4.1700. The stock has fluctuated within a day range of 4.1240 to 4.2500, while its 52-week range spans from 3.6450 to 21.4004.

What Is Neuphoria Therapeutics (NEUP) Price Target According to Analysts?

The average 12-month price target for Neuphoria Therapeutics is USD9.7667, with a high estimate of USD20 and a low estimate of USD2.3. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +133.09% Upside potential.

What Is the NEUP Premarket Price?

NEUP's last pre-market stock price is 4.1700. The pre-market share volume is 1,340.0000, and the stock has decreased by -0.0800, or -1.8800%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.